A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS. Ainos, Inc. (the “Company”), incorporated in the State of Texas in 1984, is a diversified healthcare company focused on the development of novel point-of-care testing (the “POCT”), therapeutics based on very low-dose interferon alpha (the “VELDONA”), and synthetic RNA-driven preventative medicine. Our product pipeline includes commercial-stage VELDONA Pet supplements, clinical-stage VELDONA human therapeutics and telehealth-friendly POCTs powered by the AI Nose technology platform. Our vision for AI Nose is to digitize smell, extend application beyond healthcare, and ultimately become AI’s nose. We have historically involved in the research and development of therapeutics based on VELDONA. Building on our research and development on VELDONA since inception, we are focused on commercializing a suite of VELDONA-based product candidates.
| Segment | 2023 | % of Total |
|---|---|---|
COVID 19 Antigen Rapid Test Kits Sales | $0M | 100% |
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 113K | - | - | - | - | - |
| Net Income | -15M | -15M | -14M | -14M | -3.9M | -1.5M |
| EPS | $-3.91 | $-7.80 | $-16.80 | $-128.50 | $-11.25 | $-15.00 |
| Free Cash Flow | -4.7M | -5.8M | -4.8M | -3.7M | -1.4M | -500K |
| ROIC | -60.2% | -57.2% | -50.2% | -38.9% | -37.4% | -111.2% |
| Gross Margin | 82.7% | - | - | - | - | - |
| Debt/Equity | 1.10 | 0.97 | 0.13 | 0.06 | 0.36 | -2.27 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -14M | -14M | -13M | -14M | -3.9M | -1.4M |
| Operating Margin | -12674.0% | - | - | - | - | - |
| ROE | -148.9% | -74.4% | -56.3% | -40.4% | -38.1% | - |
| Shares Outstanding | 5M | 2M | 3M | 0M | 0M | 0M |
Ainos, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Ainos, Inc. (AIMD) has a 5-year average return on invested capital (ROIC) of -59.0%. This is below average and may indicate limited pricing power.
Ainos, Inc. (AIMD) has a market capitalization of $8M. It is classified as a small-cap stock.
Ainos, Inc. (AIMD) does not currently pay a regular dividend.
Ainos, Inc. (AIMD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Ainos, Inc. (AIMD) generated $-6 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Ainos, Inc. (AIMD) has a debt-to-equity ratio of 0.97. This indicates moderate leverage.
Ainos, Inc. (AIMD) reported earnings per share (EPS) of $-7.80 in its most recent fiscal year.
Ainos, Inc. (AIMD) has a return on equity (ROE) of -74.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for Ainos, Inc. (AIMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Ainos, Inc. (AIMD) has a book value per share of $8.14, based on its most recent annual SEC filing.
No recent press releases.